Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
11 Results for "
VHL1
" in MedChemExpress (MCE) Product Catalog:
Products (11)
11 Results for "VHL1" in MCE Product Catalog:
Target:
연구분야:
SHP2-D26 isomer-1 (Compound 26) is an isomer of SHP2-D26 (HY-145162). SHP2-D26 is the first highly potent SHP2 PROTAC degrader. The induction of SHP2 degradation by SHP2-D26 requires binding to VHL-1 and SHP2 proteins, and is dependent on ubiquitin-like modification and the proteasome. SHP2-D26 can be used in the research of esophageal cancer and acute myeloid leukemia [1].
Cat. No.: HY-170824
CAS No.: 3033586-31-8
Target:
연구분야:
SMD-3236 is a SMARCA2 PROTAC degrader with a DC50 of 0.5 nM, a Dmax of 98%, and an IC50 of 42.2 nM against human SMARCA2. SMD-3236 induces proteasome- and ubiquitin-like modification-dependent degradation of SMARCA2 protein by binding to SMARCA2 and VHL-1. SMD-3236 inhibits the growth of SMARCA4-deficient cancer cells. SMD-3236 induces significant and persistent depletion of SMARCA2 in tumor tissues. SMD-3236 suppresses tumor growth in SMARCA4-deficient human cancer xenograft models. SMD-3236 can be used in research related to SMARCA4-deficient cancers such as melanoma, non-small cell lung cancer, and acute myeloid leukemia [1].
Cat. No.: HY-146022
CAS No.: 2353494-84-3
연구분야:
SIAIS117 is an ALK PROTAC degrader constructed based on Brigatinib (HY-12857) and VHL-1. SIAIS117 exhibits activity not only against wild-type ALK fusion proteins, but also effectively degrades the highly drug-resistant ALK G1202R mutant fusion protein. SIAIS117 significantly inhibits the proliferation of non-small cell lung cancer, small cell lung cancer, anaplastic large cell lymphoma, and drug-resistant cells expressing EML4-ALK G1202R. SIAIS117 can be used in relevant research on the above-mentioned malignant tumors [1].
Cat. No.: HY-174858
연구분야:
dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH) [1].
Cat. No.: HY-RS15648
Target:
연구분야:
VHL Human Pre-designed siRNA Set A contains three designed siRNAs for VHL gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-174860
CAS No.: 3064087-54-0
연구분야:
ASK1 ligand 1 is a binding ligand for ASK1 and can be used to synthesize PROTACs such as dASK1-VHL (HY-174858 )[1].
Cat. No.: HY-P76124
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: VHL; Von Hippel‑Lindau Tumor Suppressor; Von Hippel‑Lindau Disease Tumor Suppressor; VHL1; PVHL; Von Hippel‑Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase; Protein G7; Von Hippel‑Lindau Tumor Suppressor, Isoform CRA_d; Von Hippel‑Lindau Tumor Suppre
Cat. No.: HY-174861
연구분야:
(S,R,S)-AHPC-CO-C2-PEG-NHCO-C2-COOH is a synthetic E3 ubiquitin ligase ligand-linker conjugate that can be used to synthesize PROTACs such as dASK1-VHL (HY-174858) [1].
Cat. No.: HY-187391
CAS No.: 3033385-55-3
Target:
RIPK1-ligand-4 is a RIMTAC E3 recruiting ligand that indirectly recruits VHL E3 ligases by binding to RIPK1 and hijacking the endogenous RIPK1-VHL complex. RIPK1-ligand-4 can be used to synthesize the BRD4 RIMTAC-1 (HY-187390) PROTAC degrader [1].
Cat. No.: HY-122570
CAS No.: 1360616-29-0
Target:
연구분야:
VHL Ligand 38 (Compound 1) is a competitive E3 ubiquitin-protein ligase VHL inhibitor with IC50s of 4.1 and 7.0 μM in 1% and 10% DMSO, respectively. VHL Ligand 38 contains a hydroxyproline residue and an isoxazolylacetamide fragment. VHL Ligand 38 significantly inhibits the binding of a fluorescent peptide derived from HIF1α (FAM-DEALA-Hyp-YIPD) (HY-P5908F) to VHL .
Cat. No.: HY-187390
BRD4 RIMTAC-1 is a BRD4 PROTAC degrader based on the RIPK1-mediated targeted chimera (RIMTAC) technology. It hijacks the endogenous RIPK1-VHL complex via the RIPK1 inhibitor moiety to indirectly recruit the VHL E3 ligase, forming a BRD4-Compound 10-RIPK1-VHL quaternary complex, and degrades BRD4 through the ubiquitin-proteasome system (UPS). BRD4 RIMTAC-1 exhibits selectivity over other BET proteins, induces concentration- and time-dependent, reversible post-translational degradation of BRD4 without altering the target mRNA level. BRD4 RIMTAC-1 potently induces endogenous BRD4 degradation in RAW264.7 and HEK-293T cells, with DC50 values of 179.1 nM and 54.12 nM, respectively. BRD4 RIMTAC-1 can be used for the research of cancer and inflammation-related diseases [1].
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
